Market drivers - from payors, patients and regulators - mean that pharma and biopharma manufacturing is under constant pressure to increase efficiency, reduce cost and maintain quality. Many forward-thinking companies have invested in smarter manufacturing, putting lean, six sigma PAT and QbD principles into routine practice. Many are now considering a move to continuous manufacturing process. The goals are clear, build in regulatory compliance, ensure close monitoring of processes, de-risk the manufacturing chain and enable fast drug release. But achieving success is not just about process, robust analytical information is key.
Bruker's suite of mass spectrometers, NMR systems, FT-IR/FT-NIR and Raman instruments provide valuable solutions for both small molecule and biopharmaceutical drug manufacturers.